

23 April 2018

Our Ref: RFI 23017

Dear

**Freedom of Information Act 2000
Information in Relation to Metastatic Hepatocellular Carcinoma Patients**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 23 March 2018.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

Under the terms of the legislation, if you are unhappy with this response you have the right to seek a review within the Trust in the first instance. If you wish to do so, please write to me at the address below.

If after such a review you are still unhappy with the response, you have the right to appeal to the Information Commissioner who will undertake an independent review. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, SK9 5AF.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely,

**L McAree (Miss)
Head of Information Governance &
Directorate Support**

Question 1 - In the past three months, how many metastatic hepatocellular carcinoma patients were treated with:

Sorafenib (Nexavar)	This treatment is provided in the Belfast Health and Social Care Trust (BHSCT) only. For more information I would suggest you contact the BHSCT directly by emailing publicliaison@belfasttrust.hscni.net
Other active systemic anti-cancer therapy	As above
Other including palliative care	5 patients

Question 2 - In the past three months, how many metastatic renal cell carcinoma patients were treated with:

Sunitinib (Sutent)	This treatment is provided in the BHSCT only
Pazopanib (Votrient)	As above
Everolimus (Afinitor)	
Temsirolimus (Torisel)	
Cabozantinib (Cometriq)	
Nivolumab (Opdivo)	
Axinitib (Inlyta)	
Nivolumab + Ipilimumab (Opdivo + Yervoy)	
Levatinib (Lenvima) + Everolimus (Afinitor)	
Tivozanib (Fotivda)	
Other active systemic anti-cancer therapy	
Other including palliative care	None

Question 3 - In the past 3 months, how many metastatic melanoma patients were treated with:

<i>Pembrolizumab (Keytruda)</i>	This treatment is provided in the BHSCT only
<i>Nivolumab (Opdivo)</i>	As above
<i>Ipilimumab (Yervoy)</i>	
<i>Nivolumab + Ipilimumab (Opdivo + Yervoy)</i>	
<i>Dabrafenib + Trametinib (Tafinlar + Mekinist)</i>	
<i>Dabrafenib (Tafinlar)</i>	
<i>Vemurafenib (Zelboraf)</i>	
<i>Vemurafenib + cobimetinib (Zelboraf + Cotellic)</i>	
<i>Other active systemic anti-cancer therapy</i>	
<i>Other including palliative care</i>	